Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Hiddemann, 2014, How we manage follicular lymphoma., Leukemia, 28, 1388, 10.1038/leu.2014.91

Kridel, 2012, Pathogenesis of follicular lymphoma., J Clin Invest, 122, 3424, 10.1172/JCI63186

Mozessohn, 2014, Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis., Leuk Lymphoma, 55, 2502, 10.3109/10428194.2014.885513

Casulo, 2015, Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study., J Clin Oncol, 33, 2516, 10.1200/JCO.2014.59.7534

Maurer, 2014, Event-free survival at 12 months (EFS12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era [abstract]., Blood, 124, 10.1182/blood.V124.21.1664.1664

Maurer, 2014, Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy., J Clin Oncol, 32, 1066, 10.1200/JCO.2013.51.5866

Sargent, 2015, Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts) [abstract]., J Clin Oncol, 33

Pastore, 2015, Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry., Lancet Oncol, 16, 1111, 10.1016/S1470-2045(15)00169-2

Hiddemann, 2005, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group., Blood, 106, 3725, 10.1182/blood-2005-01-0016

O’Shea, 2008, The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival., Blood, 112, 3126, 10.1182/blood-2008-05-154013

Cheson, 2007, Revised response criteria for malignant lymphoma., J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403

Salles, 2011, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial., Lancet, 377, 42, 10.1016/S0140-6736(10)62175-7

Rambaldi, 2002, Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma., Blood, 99, 856, 10.1182/blood.V99.3.856

Galimberti, 2014, Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial., Clin Cancer Res, 20, 6398, 10.1158/1078-0432.CCR-14-0407

Pott, 2012, MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR., Methods Mol Biol, 971, 175, 10.1007/978-1-62703-269-8_10

Ladetto, 2013, Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders., Leukemia, 28, 1299, 10.1038/leu.2013.375

Roschewski, 2015, Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study., Lancet Oncol, 16, 541, 10.1016/S1470-2045(15)70106-3

Booth, 2014, Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence., Br J Cancer, 110, 551, 10.1038/bjc.2013.725

Federico, 2009, Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project., J Clin Oncol, 27, 4555, 10.1200/JCO.2008.21.3991

Rummel, 2013, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial., Lancet, 381, 1203, 10.1016/S0140-6736(12)61763-2

Flinn, 2014, Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study., Blood, 123, 2944, 10.1182/blood-2013-11-531327

Wilson, 2010, Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity., Lancet Oncol, 11, 1149, 10.1016/S1470-2045(10)70261-8

McCabe, 2012, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations., Nature, 492, 108, 10.1038/nature11606

Andersen, 2012, Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones., Leuk Res Rep, 2, 1

Trinh, 2013, Analysis of FOXO1 mutations in diffuse large B-cell lymphoma., Blood, 121, 3666, 10.1182/blood-2013-01-479865

Sander, 2015, PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones., Immunity, 43, 1075, 10.1016/j.immuni.2015.10.021

Wilson, 2015, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma., Nat Med, 21, 922, 10.1038/nm.3884